HD-OPM Archive
Topics › Fats & oils (saturated fat, seed oils, omega-6, olive oil)

Linoleic acid activates PPAR-gamma like pioglitazone, which may reverse plaque

Louis Nervegna · Dec 21, 2025 · ♥ 14 reactions · 0 comments · original Facebook post
Fats & oils (saturated fat, seed oils, omega-6, olive oil)Plaque, CAC & CT angiographyInsulin resistance & diabetes
AI summary & key facts

Louis links linoleic acid, PPAR-gamma activation, nuts reversing carotid plaque in PREDIMED, and pioglitazone data on plaque in an overview from Gokhan Can.

Linoleic acid (omega 6 fat) found naturally in nuts and seeds is an activator of PPAR-gamma.

See this post: ↪ Why omega-6 lowers diabetes risk: 43% lower risk in top vs bottom blood level quintile

It is an essential fat. Your body cannot make it. Without a regular dietary source of linoleic acid, you would die.

By activating PPAR-gamma, linoleic acid works similar to the diabetes drug pioglitazone— but weaker.

The drug pioglitazone may reverse plaque in humans. See below.

Nuts reversed plaque in the carotid artery in the famous PREDIMED trial. See this post: ↪ PREDIMED: nuts regressed carotid plaque and a nut-rich Mediterranean diet cut stroke 50%.

#ppargammaHD #pioglitazoneHD #linoleicacidHD #omega6HD #nutsHD #seedsHD #seedoilsHD #plaqueHD #diabetesHD #insulinresistanceHD #omega6diabetesHD #thiazolidinedionesHD


Research cited

Shared from Gokhan Can · original post

Pioglitazone for Atherosclerotic Plaque

Below is a data-rich overview of how pioglitazone (PPARγ agonist) affects atherosclerotic plaque in humans. References to specific studies and key numerical results are provided, along with practical considerations for patients.

Overview: Pioglitazone and Atherosclerotic Plaque

Pioglitazone, used primarily to improve insulin sensitivity in type 2 diabetes (T2D), has also been shown in multiple clinical trials to reduce coronary plaque volume, shift plaque composition toward a more stable phenotype, and decrease vascular inflammation. Unlike statins, which strongly reduce LDL and stabilize plaque primarily through lipid-lowering, pioglitazone’s anti-atherogenic actions appear more closely tied to reductions in inflammation, increases in adiponectin, and improved insulin sensitivity.

Major Findings From Key Studies

1) PERISCOPE Trial (Nissen et al., 2008)

2) Ogasawara et al., 2009

Why It Matters

3) Christoph et al. (2015)

4) Nakayama et al., 2010

5) Yang et al., 2012

6) Clementi et al., 2009

Despite the contradictory finding on necrotic core, overall volume decreased. Some authors theorize that as the plaque regresses, it may reorganize, transiently altering the proportion of tissue components.

7) Pioglitazone and Coronary Inflammation by 18F-FDG PET/CT

Common Themes & Mechanisms

  1. Plaque Regression
  1. Plaque Composition Stabilization
  1. Anti-Inflammatory Action
  1. Adiponectin Increase
  1. Beyond Glucose Lowering

What Should a Patient Do?

  1. Continue Standard Cardiovascular Risk Management
  1. Discuss Pioglitazone’s Risks and Benefits With Your Clinician
  1. Address Dosing and Monitoring
  1. Maintain Lifestyle Measures

Bottom Line

Multiple clinical trials using intravascular imaging—IVUS, VH-IVUS, and FDG-PET/CT—consistently demonstrate that pioglitazone can reduce coronary plaque volume, decrease necrotic core components, and lower vascular inflammation, independent of its glucose-lowering effect. By raising adiponectin and suppressing inflammatory pathways, pioglitazone is associated with stabilization or regression of atherosclerotic plaques in both diabetic and non-diabetic patients.

While these findings are highly encouraging, it is essential that patients considering pioglitazone:

In short, pioglitazone offers a valuable option to enhance plaque stability and potentially reduce cardiovascular events, but should always be integrated with comprehensive cardiovascular risk management.

References

← newer: In PREDIMED, a Mediterranean diet with nuts regressed carotiolder: Why omega-6 lowers diabetes risk: 43% lower risk in top vs b →